Patent №
US 8,513,192
Granted
2013-08-20
Filed 2011
Owner
NOVO NORDISK A/S
+1 more
Lab
—
AI components
1
evo
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
13144757
The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
AI classification
Evolutionary computation0.94
Natural language0.01
Vision0.01
Machine learning0.00
AI hardware0.00
Speech0.00
Knowledge representation0.00
Planning0.00
Ownership
NOVO NORDISK A/S
assignment · 268250604
NOVO NORDISK HEALTHCARE AG
assignment · 351370469
Assignors
OLSEN, OLE HVILSTED, BREINHOLT, JENS, SCHIODT, CHRISTINE BRUUN, DEMUTH, HELLE, NORSKOV-LAURITSEN, LEIF, THYGESEN, PETER
On an employer assignment, the assignors are typically the inventors.
From the same owner
INSULIN TITRATION ALGORITHM BASED ON PATIENT PROFILEUS 12,249,425 · 2025SYSTEMS AND METHODS FOR OPTIMIZATION OF BOLUS TIMING RELATIVE TO MEAL EVENTSUS 11,631,486 · 2023DOSE CAPTURING ASSEMBLY WITH SECONDARY IMAGE ANALYSIS FEATUREUS 11,623,049 · 2023SYSTEMS AND METHODS FOR ANALYSIS OF INSULIN REGIMEN ADHERENCE DATAUS 11,562,816 · 2023REGIMEN ADHERENCE MEASURE FOR INSULIN TREATMENT BASED ON GLUCOSE MEASUREMENTS AND INSULIN PEN DATAUS 11,464,447 · 2022SYSTEMS AND METHODS FOR ADJUSTING A BASAL/BOLUS RATIO IN AN INSULIN REGIMENUS 11,462,313 · 2022DRUG INJECTION DEVICE WITH DEFLECTABLE TRANSDUCERSUS 11,369,748 · 2022BASAL TITRATION WITH ADAPTIVE TARGET GLUCOSE LEVELUS 11,373,746 · 2022